Health Care/Hospital

Healthcare Holding Schweiz Acquires Stake in Medddbase International

Healthcare Holding Schweiz AG, a leading service provider and distributor of medical technology inSwitzerland, expands its portfolio through the acquisition of a majority stake in Medddbase International AG, which includes Medddbase Schweiz AG and Medddbase Deutschland GmbH. Healthcare Holding Sc...

2026-01-06 19:19

Clarivate Identifies Eleven Potential Blockbuster and Transformative Therapies in its 2026 Drugs to Watch Report

Anticipated advancements in weight loss, diabetes, oncology, rare conditions and protein degraders poised to reshape patient care LONDON, Jan. 6, 2026 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT

2026-01-06 16:21 778

Ark Biopharmaceutical Receives China Marketing Authorization for Azstarys® for the Treatment of ADHD

SHANGHAI, Jan. 6, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced thatChina's National Medical Products Administration (NMPA) has approved the New Drug Application for Serdexmethylphenidate Chloride and Dexmethylphenidate Hydrochloride Capsules (Azstarys®)...

2026-01-06 14:45 809

Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery Platform

SINGAPORE, Jan. 6, 2026 /PRNewswire/ -- Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical's HLA-G targeted exosome program.  Shine-On Biomedical sponsored Esco Aster in 2023 for cGMP service...

2026-01-06 12:03 1531

Everest Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference

SHANGHAI, Jan. 6, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced thatIan Woo, President and Chief Fina...

2026-01-06 07:58 1799

BoomerangFX Expands UK and EMEA Operations With New UK Office and Senior Appointments as demand for AI Clinic Co-Pilot AUVIA™ Drives Record Growth in Healthcare

Expansion builds on global offices in Miami, Toronto, London, and Sydney as BoomerangFX advances its mission to become the foundational AI-powered operating platform for private-pay healthcare worldwide. LONDON, Jan. 6, 2026 /PRNewswire/ -- BoomerangFX, a global AI-powered clinic software and ma...

2026-01-06 03:56 1782

Kelun-Biotech Receives Investigational New Drug Approval for ITGB6-Targeted ADC SKB105 from the NMPA

CHENGDU, China, Jan. 5, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that its Investigational New Drug (IND) application for SKB105 (also known as CR-003), an internally developed integrin beta-6 (ITGB6)-targeted ant...

2026-01-05 20:00 1977

Sisram Medical Reports Completion of NIFDC Testing for DAXXIFY in China

Marking a Key Milestone Toward Market Launch and Strengthening Sisram's Premium Aesthetics Portfolio HONG KONG, Jan. 5, 2026 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK; together with its subsidiaries collectively referred to as the"Group"), a global wellness group off...

2026-01-05 17:36 1665

Kelun-Biotech Announces Breakthrough Therapy Designation Granted in China for Sacituzumab Tirumotecan (sac-TMT) in Combination with Immunotherapy Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC

CHENGDU, China, Jan. 5, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company," 6990.HK) today announced that its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870) (佳泰莱®) in combination wi...

2026-01-05 17:29 2349

GenEditBio Receives FDA Clearance of IND Application for Its Lead In Vivo Genome-Editing Program GEB-101 for TGFBI Corneal Dystrophy

HONG KONG, Jan. 5, 2026 /PRNewswire/ -- GenEditBio Limited ("GenEditBio"), a clinical-stage biotechnology startup focusing on genome-editing therapeutic solutions, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application...

2026-01-05 12:07 1991

C&R Research, the 'K-Clinical Hub', Strengthens Partnerships in Indonesia

Accelerating Indonesia Collaboration through Global Clinical Capabilities SEOUL, South Korea, Jan. 5, 2026 /PRNewswire/ -- C&R Research, founded in 1997 as Korea's first full-service Contract Research Organization (CRO), has played a pivotal role in advancing the Korean clinical trial industry an...

2026-01-05 10:00 2379

Ascletis Announces U.S. FDA IND Clearance for 13-Week Phase II Study of Its Oral Small Molecule GLP-1, ASC30, in Participants with Diabetes

-The Phase II study for diabetes is a 13-week, randomized, double-blind, placebo-controlled and multi-center study to evaluate the efficacy, safety, and tolerability of ASC30 in participants with diabetes. Enrollment is expected to begin in the first quarter of 2026. -ASC30 demonstrated placebo-...

2026-01-05 08:10 2225

Babies Bliss Establishes a New Standard for Fertility Wellness in Singapore with a Whole-Person, Cycle-Aware Model

Singapore-based Fertility Wellness House positions complementary care as long-term support alongside IVF and assisted fertility treatments SINGAPORE, Jan. 5, 2026 /PRNewswire/ -- Babies Bliss, a leading fertility wellness house inSingapore, is redefining how fertility journeys are supported thro...

2026-01-05 07:00 2065

Daingt Co., Ltd. Launches New Gim Products Based on Raw Material Data, Expanding Its Quality-Focused Lineup

SEOUL, South Korea, Jan. 4, 2026 /PRNewswire/ -- Daingt Co., Ltd. announced the launch of new gim (seaweed) products developed based on its accumulated production experience and raw material data. The newly introduced products were developed by actively leveraging Daingt's extensive database of ...

2026-01-04 08:00 3271

Rising Through Challenge: Living Phoenix's 2026 New Year Message POGMENT Biomimetic Collagen

CHENGDU, China, Jan. 1, 2026 /PRNewswire/ -- As the Year of the Horse begins, bringing new momentum and promise,Living Phoenix—a pioneer in next-generation biomaterials—wishes all friends, partners, and users a joyful New Year. May you stay young, steady, and ready to gallop forward into 2026. ...

2026-01-01 12:36 4366

POGMENT Biomimic Collagen Reacquired Recognition, Founder Appointed as Industrial Mentor for Master's Students at East China Normal University, Awarded 2025 Innovation Leadership Award

CHENGDU, China, Dec. 31, 2025 /PRNewswire/ -- On December 27, the 2025 Master of Engineering Management (MEM) Industry Mentor Orientation and Appointment Ceremony was held at the Wenshi Building on the Putuo Campus of East China Normal University (ECNU), located at No. 3663 Zhongshan North Road, ...

2025-12-31 17:21 6215

Life-Space TrioBiotic Series Lands in Southeast Asia, Revolutionizing Gut Health with Triple-Action Formula

BANGKOK, Dec. 31, 2025 /PRNewswire/ -- A significant shift is underway in the regional health and wellness landscape as the innovative Life-Space TrioBiotic supplement series officially enters the Southeast Asian market. The launch introduces a cutting-edge "three-in-one" approach to gut health, ...

2025-12-31 15:46 6185

KLMBio Accelerates Global Expansion in Bone Graft Market with Human Tissue-Based Medical Devices

SEOUL, South Korea, Dec. 31, 2025 /PRNewswire/ -- KLMBio, a manufacturer and exporter of human tissue-based medical devices, is accelerating its global business expansion by strengthening its high-value tissue-based product portfolio to target the rapidly growing global bone graft market. The gl...

2025-12-31 12:44 3086

Qiming Venture Partners' Insilico Medicine Successfully Lists on Hong Kong Stock Exchange

SHANGHAI, Dec. 31, 2025 /PRNewswire/ -- Insilico Medicine (03696.HK), a global leader in AI-driven drug discovery and a portfolio company of Qiming Venture Partners, today successfully listed on the Hong Kong Stock Exchange (HKEX). The listing marks the largest biotech IPO on theHong Kong stock m...

2025-12-31 08:55 3894

HKSH Medical Group and Southern University of Science and Technology Collaborate for Medical and Medical Physics Training, Enhancing Medical Education and Research Innovation

HONG KONG, Dec. 29, 2025 /PRNewswire/ -- HKSH Medical Group ("HKSH") and Southern University of Science and Technology ("SUSTech") officially signed a Memorandum of Understanding ("MOU") on15 December 2025, a significant initiative to deepen collaboration betweenHong Kong and the Chinese Mainland...

2025-12-29 16:12 3050
12345 ... 551